Orchid Pharma Limited · NSE:ORCHPHARMA

Orchid Pharma — Q4 FY2023-24 Earnings Presentation

10 slides from Orchid Pharma's earnings presentation, May 23, 2024

  1. Slide 1: Exchange filing cover letter for Investor Presentation Q4 FY 2023-24

    May 23, 2024 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Investors Presentation Q4-F.Y. 2023-24 – Orchid Pharma Limited

  2. Slide 2: Orchid Pharma Limited Financials Q4 & FY 2023-24

    Orchid Pharma Limited Financials Q4 & FY 2023-24 • All results in standalone basis. • * These are approx. nos. for exact nos. pls refer financials .

  3. Slide 3: Financial Highlights QTR-4 FY 23-24

    Financial Highlights QTR-4 FY 23-24 3% 23% 1% 37% 12% 472% -50% 72%

  4. Slide 4: Financial Highlights Full Year

    Financial Highlights Full Year Growth 12M 23-24 9M 23-24 6M 23-24 3M 23-24 Criteria Turnover 23.1% 32.1% 28.9% 39.6% EBIDTA 36.9% 60.9% 43.1% 56.9% PBT 471.6% 674.8% 278.2% 176.6% PAT 71.6% 674.8% 278.2% 176.6% * Comparison YOYY

  5. Slide 5: Financial Performance Summary

    Financial Performance Summary 12M-31st 12M-31st (Rs/Crore) Q4-2024 Q4-2023 Change % Change % Mar’24 Mar’23 Sales 217.1 209.9 +3% 819.4 665.9 +23% Other Income 12.9 1.7 30.4 19.4 COGS 128.1 118.9 484.6 384.6 Employee Exp 17.6 16.4 69.6 65.4 Other Exp 42.5 34.9 154.6 132.3 EBITDA 41.8 41.4 +1% 141.0 1

  6. Slide 6: Turnover (In Cr.)

    Turnover (In Cr.) 900.0 819.4 800.0 700.0 665.9 600.0 557.0 481.2 450.7 500.0 400.0 300.0 217.1 180.2 209.9 200.0 120.5 110.1 100.0 - Mar-20 Mar-21 Mar-22 Mar-23 Mar-24 12M Mar Q4 -Mar

  7. Slide 7: EBIDTA, PBT & PAT as % to Sales 12M

    EBIDTA, PBT & PAT as % to Sales 12M 20.0% 15.0% 17.2% 14.3% 15.5% 10.0% 11.9% 11.6% 11.2% 5.0% 7.0% 8.3% 0.0% 2.4% -5.0% -10.0% -9.5% -15.0% -20.0% -18.4% -25.0% -21.3% Mar-20 Mar-21 Mar-22 Mar-23 Mar-24 EBITDA PBT PAT

  8. Slide 8: P&L Analysis – Gross Margin % to Sales

    P&L Analysis – Gross Margin % to Sales Gross Margin for Yearly 70.0% 58.4% 60.0% 49.1% 50.0% 43.6% 42.2% 40.9% 40.0% 30.0% 20.0% 10.0% 0.0% FY 19-20 FY 20-21 FY 21-22 FY 22-23 FY 23-24

  9. Slide 9: P&L Analysis – Exp. % to Sales 12M

    P&L Analysis – Exp. % to Sales 12M 45.0% 41.6% 40.0% 35.0% 30.0% 25.0% 22.0% 22.5% 19.9% 18.9% 20.0% 14.9% 14.3% 15.0% 10.8% 9.8% 8.5% 10.0% 5.0% 0.0% Mar-20 Mar-21 Mar-22 Mar-23 Mar-24 Emp Benefit Other Exp

  10. Slide 10: Thank You

    Thank You

Orchid Pharma — Q4 FY2023-24 Earnings Presentation on 6ix